GeneDx Drops 38% in a Month as Earnings Loom in Ten Days

WGS has shed 38% over the past month and another 16% in the last session alone, entering its November 3 earnings date with short sellers holding firm, options traders more defensive than usual, and the Street's price targets sitting well above a stock that has been in freefall.

The positioning tells a story of genuine disagreement rather than panic short selling. Short interest runs at 19.3% of the free float, a high absolute level that has actually drifted lower over the past month. It peaked near 21% in mid-September and has since eased by about 10%, suggesting some shorts covered into weakness rather than pressing the position. That drift is notable given the scale of the price collapse: short sellers are not piling in aggressively at these levels. Availability in the lending market is also loose, at over 510% of current short interest, meaning there is no supply constraint for new borrows and no mechanical squeeze pressure building. Cost to borrow has ticked up 19% over the past week to 0.47%, but remains low in absolute terms. Together, the picture is one of an established short base that is trimming cautiously, not a crowd rushing to add. Options traders read differently: the put/call ratio closed at 1.09 on October 23, above its 20-day average of 0.94, reflecting more demand for downside protection as the earnings date draws closer. The ORTEX short score stands at 64.4, elevated but slightly off its recent high of 68.6 hit on October 13.

The Street remains constructively positioned but has been adjusting after a difficult first half. The most recent analyst action, Guggenheim raising its target to $83 while maintaining Buy in early October, captures the broader tone: firms have kept positive ratings but trimmed their numbers materially since a series of post-Q1 cuts in May, when Canaccord, Wells Fargo, Guggenheim, and BTIG all slashed targets after the company cut its full-year revenue guide by $65 million. The consensus mean target stands at $93.50, implying roughly 66% upside from the current $56.15, a gap that reflects how sharply the stock has moved rather than a genuine surge in analyst optimism. The valuation has re-rated hard: the trailing PE has compressed by 29 points over the past 30 days, and EV/EBITDA is down nearly 10 turns over the same window. The bull case centres on reimbursement progress, including Carelon's June 2026 recognition of whole-genome sequencing as medically necessary, a rising mix of higher-value exome and genome tests, and the Fabric Genomics acquisition. The bear case points to the Q1 miss on revenue, margins, and net income, alongside a cut to core exome and genome volume growth targets, with questions about forecasting credibility now hanging over the November print.

The ownership register adds another layer of interest. Keith Meister, whose Corvex Management holds roughly 16% of shares, has an active Schedule 13D on file, the most newsworthy category of shareholder registration. His stake has been disclosed at 17.9% of the class and has not changed per the most recent filing from May 2026. Icahn School of Medicine at Mount Sinai also carries a 13D filing, though its stake has fallen to 4.89% from 6.1% as of February 2025. Casdin Capital added 700,000 shares in the quarter to June 30, bringing its holding to 12.4% of shares. ARK Investment Management and BlackRock each crossed the 5% disclosure threshold this summer. The concentration of large, active holders alongside an equally large short base creates a structure where the November 3 print carries unusual weight. Insider activity in September was net negative, with CEO Katherine Stueland and CFO Kevin Feeley both selling at prices around $94 to $99, well above current levels. Those sales were not under 10b5-1 plans, though the volumes were modest. Taken together, the insider selling into strength in September, now followed by a 40% collapse, will add scrutiny to how management frames the earnings discussion.

The earnings history gives some context for how this stock has behaved around prints. The last reported quarter in August produced a one-day gain of around 3% and a five-day move of 20%. The quarter before that, also in August in the ORTEX history, showed a similar pattern with gains of roughly 9% on day one and 20% over five days. Those were positive surprises after a guidance cut had reset expectations. The question for November 3 is whether a similar reset is already priced in after the month's decline, or whether the miss on Q1 forecasting quality makes the Street more cautious about giving management the benefit of the doubt this time around. Wikipedia attention for the stock has spiked sharply, with an attention z-score of 4.2 as of October 19, the highest retail attention reading relative to its own 90-day history, suggesting the price move has caught broader notice beyond the specialist genomics investor base.

What to watch heading into November 3: whether management revises the $475 to $490 million full-year revenue guide again, how ASPs are trending given the prior concern about pricing softness near $3,300, and whether the short base shows any sign of covering further or rebuilding as the print approaches.